Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 3/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.58 |
| ▸ | PTK2B | Q14289 | 10/20 | 0.58 |
| ▸ | ULK1 | O75385 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570395 | 0.92 | ULK1 (0.51) | BCL6PTK2PTK2BULK1CYP1A2 | |
| SCHEMBL16570474 | 0.86 | BCL6 (0.59) | BCL6PTK2PTK2BULK1KDR | |
| SCHEMBL16570339 | 0.78 | PTK2 (0.55) | BCL6PTK2PTK2BULK1KDR | |
| SCHEMBL343790 | 0.76 | ABL1 (0.47) | PTK2KDRSYKCYP1A2 | |
| SCHEMBL10167382 | 0.75 | JAK3 (0.48) | PTK2 | |
| SCHEMBL10167393 | 0.75 | EGFR (0.45) | PTK2PTK2BPLK1KDRSYK | |
| SCHEMBL31299861 | 0.74 | PTGS1 (0.52) | PTK2 | |
| SCHEMBL342369 | 0.74 | CDK1 (0.58) | PTK2KDRSYK | |
| SCHEMBL344496 | 0.74 | CDK4 (0.62) | PTK2KDR | |
| SCHEMBL15428629 | 0.74 | CDK4 (0.48) | PTK2KDRSYKCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | BCL6 704/4885PTK2 2/4885PTK2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.